%0 Journal Article %1 Snapinn2006 %A Snapinn, Steven %A Chen, Mon-Gy %A Jiang, Qi %A Koutsoukos, Tony %D 2006 %J Pharmaceutical statistics %K ClinicalTrialsasTopic ClinicalTrialsasTopic:methods DataInterpretation EndpointDetermination Ethics EvaluationStudiesasTopic Humans Medical Models MulticenterStudiesasTopic MyocardialInfarction MyocardialInfarction:drugtherapy Probability ResearchDesign SampleSize Statistical StochasticProcesses TimeFactors RCT %N 4 %P 273-81 %R 10.1002/pst.216 %T Assessment of futility in clinical trials. %U http://www.ncbi.nlm.nih.gov/pubmed/17128426 %V 5 %X The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research. There are various approaches that have been proposed to assess futility, including stochastic curtailment, predictive power, predictive probability, and group sequential methods. In this paper, we describe and contrast these approaches, and discuss several issues associated with futility analyses, such as ethical considerations, whether or not type I error can or should be reclaimed, one-sided vs two-sided futility rules, and the impact of futility analyses on power. %@ 1539-1604; 1539-1604

@article{Snapinn2006, abstract = {The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research. There are various approaches that have been proposed to assess futility, including stochastic curtailment, predictive power, predictive probability, and group sequential methods. In this paper, we describe and contrast these approaches, and discuss several issues associated with futility analyses, such as ethical considerations, whether or not type I error can or should be reclaimed, one-sided vs two-sided futility rules, and the impact of futility analyses on power.}, added-at = {2023-02-03T11:44:35.000+0100}, author = {Snapinn, Steven and Chen, Mon-Gy and Jiang, Qi and Koutsoukos, Tony}, biburl = {https://www.bibsonomy.org/bibtex/20765b6855b6e67734c67243d7b96e3d2/jepcastel}, city = {Amgen Inc., One Amgen Center Drive, 24-2-C, Thousand Oaks, CA 91320, USA. ssnapinn@amgen.com}, doi = {10.1002/pst.216}, interhash = {a41d0b1a16fcf2399233af990c7b6280}, intrahash = {0765b6855b6e67734c67243d7b96e3d2}, isbn = {1539-1604; 1539-1604}, issn = {1539-1604}, journal = {Pharmaceutical statistics}, keywords = {ClinicalTrialsasTopic ClinicalTrialsasTopic:methods DataInterpretation EndpointDetermination Ethics EvaluationStudiesasTopic Humans Medical Models MulticenterStudiesasTopic MyocardialInfarction MyocardialInfarction:drugtherapy Probability ResearchDesign SampleSize Statistical StochasticProcesses TimeFactors RCT}, note = {7401<m:linebreak></m:linebreak>LR: 20071115; JID: 101201192; ppublish;<m:linebreak></m:linebreak>Mesures de contrast; RCT}, number = 4, pages = {273-81}, pmid = {17128426}, timestamp = {2023-05-04T08:59:38.000+0200}, title = {Assessment of futility in clinical trials.}, url = {http://www.ncbi.nlm.nih.gov/pubmed/17128426}, volume = 5, year = 2006 }